Introduction {#s1}
============

The widespread use of genetic biomarkers as surrogate endpoints aiming to describe risks, exposures, intermediate effects of treatments, and biologic mechanisms is a goal that scientists have long been pursuing. The adoption of any genetic test as a surrogate biomarker requires previous demonstration of its analytical and clinical validity as well as its clinical utility, and increasing the predictive capacity of genetic biomarkers is one of the major problems that we have to solve in order to transfer advances in pharmacogenomics to routine clinical practice. Determination of the polymorphic acetylation (*NAT2* genotype or phenotype) was initially proposed to predict adverse reactions in patients with tuberculosis receiving isoniazid, prior to the concomitant administration of procainamide and phenytoin, and to analyze the role of NAT2 in drug interactions. These effects, together with the role of *NAT2* in cancer risk, in non-malignant spontaneous disorders and in drug response and toxicity, make *NAT2* a relevant target for pharmacogenomic testing in clinical practice [@pone.0044629-Agundez1], [@pone.0044629-Andrade1].

Nearly fifty years ago, Evans et al. demonstrated that acetylation of isoniazid was bimodally distributed and that the *in vivo* acetylation status was inheritable [@pone.0044629-Evans1], [@pone.0044629-Evans2]. Since then, traditional phenotype determination by inference from genetic analyses has classified the population in three groups: rapid, intermediate and slow acetylators. Although this classification of individuals into three phenotype categories is widely accepted, it would be desirable to refine further the predictive capacity of acetylation pharmacogenomic testing [@pone.0044629-Agundez2]. Heterologous expression of NAT2 allozymes provided indirect evidence suggesting a differential effect of *NAT2* variant alleles and hence heterogeneity within the slow acetylation phenotype (reviewed in [@pone.0044629-Hein1]).

This study aims to analyze whether this evidence of heterogeneity within rapid and slow acetylators exists *in vivo*, whether commonly used pharmacogenomic tests are adequate for the inference of phenotype subcategories, and to measure the activities for such phenotype subcategories. Because acetyl metabolites may be pharmacologically active, or function as intermediates in toxic metabolic pathways, further refinement in phenotype prediction may help to identify risks associated to one or more of such phenotype subcategories.

Methods {#s2}
=======

The subjects were drawn from a study previously described [@pone.0044629-Anderson1], [@pone.0044629-Anderson2], [@pone.0044629-Zhang1]. Briefly, cases (n = 93), of newly diagnosed cancer of the exocrine pancreas were recruited from all hospitals in the 7-county metropolitan area of the Twin Cities, Minnesota and the Mayo Clinic (from the latter, only cases residing in the Upper Midwest of the US were recruited). Controls (n = 411) were randomly selected from the general population and frequency matched to cases by age and sex ([Table 1](#pone-0044629-t001){ref-type="table"}). All were Caucasian. Each participant provided written, informed consent prior to interview and blood draw. The study was approved by the Institutional Review Boards of the University of Minnesota and The Mayo Clinic, USA and by the Ethics Committee of the University of Extremadura, Spain.
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###### Characteristics of the individuals included in the study.

![](pone.0044629.t001){#pone-0044629-t001-1}

                                             Overall study group   Overall study group   Individuals selected   Individuals selected
  ----------------------------------------- --------------------- --------------------- ---------------------- ----------------------
  Age years (mean ± SD)                           65.3±11.3             65.7±13.0             65.6±11.2              66.0±12.4
  Never smokers (n; %)                           104 (33.3%)           113 (58.9%)            89 (32.5%)             98 (60.1%)
  Past smokers (n; %)                            167 (53.5%)           59 (30.7%)            147 (53.6%)             47 (28.8%)
  Current smokers (n; %)                         41 (13.1%)            20 (10.4%)             38 (13.9%)             18 (11.0%)
  Pack-years (mean ± SD)                          37.4±30.6             23.7±21.2             37.8±30.7              23.2±19.9
  Non-drinkers/drinkers                            112/200                95/97                 96/178                 80/83
  Servings of alcohol per week(mean ± SD)         9.1±11.2               4.9±5.2               9.4±11.6               5.2±5.4
  Cases/Controls (n)                               63/249                30/162                 53/221                 20/141

Individuals selected for phenotype inference refinement correspond to 435 individuals with genotypes NAT2\*4/\*4, \*4/\*5, \*4/\*6, \*5/\*5, \*5/\*6 or \*6/\*6 and phenotype/genotype concordance.

Pack-years calculation includes smokers and ex-smokers. Servings of alcohol per week include drinkers only.

In vivo NAT2 activity was measured with a widely used caffeine-based assay, as described by Butler et al. [@pone.0044629-Butler1] with minor modifications as described elsewhere [@pone.0044629-Anderson2], [@pone.0044629-Gross1]. The caffeine assay is highly accurate and reproducible, and it is considered as a gold standard for acetylation phenotyping. Details on accuracy and reproducibility were published elsewhere [@pone.0044629-Butler1], [@pone.0044629-Miners1], [@pone.0044629-McQuilkin1], [@pone.0044629-Bolt1], [@pone.0044629-Tang1]. In brief, subjects ingested 200 mg of caffeine, following an overnight fast. Subjects refrained from the consumption of caffeine- and methylxanthine-containing foods and beverages from midnight until 5 h after the dose of caffeine. A urine specimen was collected 5 h after the administration of caffeine and samples were acidified and stored as described elsewhere [@pone.0044629-Gross1]. Regarding HPLC analysis, 200 µl of urine were saturated with 125 mg of ammonium sulfate, and 6.0 ml of chloroform:isopropanol (95∶5) were added. Each sample was vortexed and centrifuged, and the organic phase was removed and evaporated to dryness. The residue was resuspended in 250 µl of 0.05% acetic acid, filtered, and frozen until analysis. Fifty µl of the extract were injected onto a Beckman C18 Ultrasphere octadecylsilane column (25 cm in length, 4.6-mm diameter, 5-µm particle size) and eluted with a 0.05% acetic acid-methanol solvent (flow rate, 1.2 ml/min).

Acetylation phenotype was assigned on the basis of a molar AFMU/1X ratio, which served as quantitative determinant of acetylation capacity with a cut-off value = 0.66 (log AFMU/1X = −0.18) in agreement with previous studies [@pone.0044629-Gross1].

*NAT2* genotyping aimed to identify the signature SNPs for alleles corresponding to the *NAT2\*5, NAT2\*6, NAT2\*7* and *NAT2\*14* clusters, that is, rs1801280 (I114T), rs1799930 (R197Q), rs1799931 (G286E) and rs1801279 (R64Q), respectively. Although several *NAT2* alleles have been described (for an updated list of *NAT2* alleles and haplotypes see the website <http://louisville.edu/medschool/pharmacology/consensus-human-arylamine-n-acetyltransferase-gene-nomenclature/nat_pdf_files/Human_NAT2_alleles.pdf>), the SNPs analyzed in this study identify the vast majority of slow *NAT2* variant allele clusters [@pone.0044629-Agundez3], [@pone.0044629-Selinski1]. Genotyping was carried out by the use of TaqMan®probes (details available in [Table S1](#pone.0044629.s001){ref-type="supplementary-material"}). For every SNP analyzed, twenty samples with heterozygous genotypes and up to twenty samples with homozygous genotypes (homozygous non-mutated and homozygous mutated when available), were determined as blind duplicates. In all samples with genotype/phenotype discordance (n = 32) the genotypes were confirmed by the use of PCR-based mutation-specific amplification as described elsewhere [@pone.0044629-Anderson2] or by direct sequencing of the amplified fragments. In all cases the genotypes fully corresponded to those obtained with TaqMan probes. Haplotype assignation and phenotype inference: All possible haplotypes combining the four SNPs analyzed were constructed and their frequencies were analyzed by using PHASE and the *NAT2* haplotype table described elsewhere [@pone.0044629-Agundez3]. Phenotype inference was carried out as described elsewhere [@pone.0044629-Agundez3]. Putative departures of Hardy-Weinberg Equilibrium were calculated by using the software Haploview 4.1. Continuous variables (acetylation ratios), expressed as mean (SD), were compared with the Student' T test, and tests for trend were calculated with the Spearman's rank correlation by using the statistical software SPSS 15.0 for Windows (SPSS Inc. Chicago, Illinois, USA). A *p* value \<0.05 was considered significant. When multiple comparisons were made, adjustments for multiple comparisons were carried out according to Bonferroni's procedure.

Results {#s3}
=======

The SNP frequencies and the genotypes observed in the 504 participants are summarized in [Table 2](#pone-0044629-t002){ref-type="table"}. The degree of phenotype/genotype concordance by using the traditional phenotype classification (i.e. rapid/slow phenotypes), where *NAT2\*4* containing genotypes are considered a rapid phenotype, and other genotypes a slow phenotype, was equal to 93.7%. We selected 435 individuals with genotypes *NAT2\*4/\*4*, *\*4/\*5*, *\*4/\*6*, *\*5/\*5*, *\*5/\*6* and *\*6/\*6* and phenotype/genotype concordance for further analyses. These corresponded to 73 cases and 362 control subjects. Carriers of variant alleles *NAT2\*14* were not included in the analyses, because these alleles were not present in the study population ([Table 2](#pone-0044629-t002){ref-type="table"}). In addition, carriers of the variant alleles *NAT2\*7* were not included in the comparisons because these alleles were rare in the population study ([Table 2](#pone-0044629-t002){ref-type="table"}).

10.1371/journal.pone.0044629.t002

###### *NAT2* SNP frequencies observed in the present study.
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  *SNP identifier*                        Amino Acid    No.   Observedfrequency (%)   Expectedfrequency (%)   Hardy Weingberg's P
  -------------------------------------- ------------- ----- ----------------------- ----------------------- ---------------------
  **rs1801280 (** ***NAT2\*5*** **)**                                                                        
  **T/T**                                 114 Ile/Ile   162           32.14                   31.64          
  **T/C**                                 114 Ile/Thr   243           48.22                   49.22                  0.647
  **C/C**                                 114 Thr/Thr   99            19.64                   19.14          
  **rs1799930 (** ***NAT2\*6*** **)**                                                                        
  **G/G**                                 197 Arg/Arg   263           52.18                   52.88          
  **G/A**                                 197 Arg/Gln   207           41.07                   39.68                  0.430
  **A/A**                                 197 Gln/Gln   34            6.75                    7.44           
  **rs1799931 (** ***NAT2\*7*** **)**                                                                        
  **G/G**                                 286 Gly/Gly   464           92.06                   91.84          
  **G/A**                                 286 Gly/Glu   38            7.54                    7.99                   0.209
  **A/A**                                 286 Glu/Glu    2            0.40                    0.17           
  **rs1801279 (** ***NAT2\*14*** **)**                                                                       
  **G/G**                                 64 Arg/Arg    504           100.0                   100.0          
  **G/A**                                 64 Arg/Gln     0            000.0                   00.0                  (--.--)
  **A/A**                                 64 Gln/Gln     0            000.0                   00.0           

Expected frequencies are calculated from observed allele frequency.

[Table 3](#pone-0044629-t003){ref-type="table"} shows the acetylation capacity of the six genotype categories analyzed in the study. The individuals with the genotype categories *NAT2\*4/\*5* and *NAT2\*4/\*6* showed similar acetylation values. However, for the rest of individuals, each genotype category corresponded to a distinct phenotype category, with non-overlapping 95% confidence intervals for the activity, and in all cases the differences between these categories were statistically significant. This provides *in vivo* evidence that in the absence of *NAT2\*4* alleles, variant alleles *NAT2\*5* and *NAT2\*6* confer different acetylation capacity. In addition, a gene-dose for these variant alleles can be observed within the slow acetylator phenotype, as there is a statistically significant trend to slower acetylation capacity among individuals with the genotypes as follows: *NAT2\*5/\*5*\>*NAT2\*5/\*6*\>*NAT2\*6\*6* (Spearman\'s rank correlation with the number of *NAT2\*6* alleles, (log AFMU/1X = −0.359); *P*\<0.001). These findings were not influenced by the sex of participants, age, smoking status, pack-years, drinking status, servings of alcohol per week as stated by multivariable linear regression, or by the case-control status ([Table 4](#pone-0044629-t004){ref-type="table"}, [Table S2](#pone.0044629.s002){ref-type="supplementary-material"}). The effect of *NAT2\*7 in vivo* could not be elucidated because of the low allele frequency in the study population. We identified only two carriers of the alleles *NAT2\*7* in homozygosity, with metabolic ratios equal to −0.51 and −0.96. The mean value (−0.74), is close to the mean value for carriers of the *NAT2\*6/\*6* genotypes, thus suggesting that the *NAT2\*7* alleles in homozygosity may confer a very slow acetylation phenotype; although due to the sample size the comparisons of the acetylation phenotype were not statistically significant. [Table S3](#pone.0044629.s003){ref-type="supplementary-material"} includes details of the log AFMU/1X ratios of carriers of *NAT2\*7*.

10.1371/journal.pone.0044629.t003

###### Acetylation ratios (log AFMU/1X) in subjects with different *NAT2* genotypes.
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  Phenotype                 Genotype             Number            Mean Ratio              SD              95% CI min          95% CI max
  -------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  **Overall rapid**     ***NAT2\*4/any***        **197**            **0.209**           **0.155**           **0.182**           **0.226**
  Rapid                 ***NAT2\*4/\*4***          36                 0.327               0.169               0.270               0.385
  Rapid-Intermediate    ***NAT2\*4/\*5***          95                 0.170               0.139               0.142               0.199
  Rapid-Intermediate    ***NAT2\*4/\*6***          66                 0.186               0.141               0.151               0.220
  **Overall Slow**        **Slow/Slow**          **238**           **−0.537**           **0.147**          −**0.556**          −**0.518**
  Slow                  ***NAT2\*5/\*5***          91              **−**0.480             0.140              −0.509              −0.451
  Slow                  ***NAT2\*5/\*6***          115               −0.551               0.131              −0.575              −0.527
  Slow                  ***NAT2\*6/\*6***          32                −0.646               0.149              −0,698              −0,592
                                                                                                                           
  **T-test**              **Genotype**      ***NAT2\*4/\*5***   ***NAT2\*4/\*6***   ***NAT2\*5/\*5***   ***NAT2\*5/\*6***   ***NAT2\*6/\*6***
                        ***NAT2\*4/\*4***       p\<0.0001           p\<0.0001           p\<0.0001           p\<0.0001           p\<0.0001
                        ***NAT2\*4/\*5***                           p = 0.574           p\<0.0001           p\<0.0001           p\<0.0001
                        ***NAT2\*4/\*6***                                               p\<0.0001           p\<0.0001           p\<0.0001
                        ***NAT2\*5/\*5***                                                                  p = 0.0002           p\<0.0001
                        ***NAT2\*5/\*6***                                                                                      p = 0.0005

The 435 individuals (73 cases and 362 control subjects) with genotypes *NAT2\*4/\*4, \*4/\*5, \*4/\*6, \*5/\*5, \*5/\*6 and \*6/\*6* and phenotype/genotype concordance were included in the comparison.

According to multiple comparison adjustment of the 15 genotype pairs according Bonferroni's procedure, a *P* value ≤0.0033 is considered as significant. Individual number for p values \<0.0001 are rounded as "p\<0.0001".

10.1371/journal.pone.0044629.t004

###### Effect of the case-control status on the Acetylation ratios (log AFMU/1X) in subjects with different *NAT2* genotypes.
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  Genotype                  Status        Mean Log ratio (SD)   95% CI min   95% CI max   Inter-group comparison
  ------------------- ------------------ --------------------- ------------ ------------ ------------------------
  ***NAT2\*4/\*4***      Case (n = 7)        0.273 (0.181)        0.105        0.441     
                       Control (n = 29)      0.341 (0.167)        0.277        0.404           *p* = 0.373
  ***NAT2\*4/\*5***     Case (n = 20)        0.157 (0.197)        0.065        0.249     
                       Control (n = 75)      0.181 (0.117)        0.154        0.209           *p* = 0.605
  ***NAT2\*4/\*6***      Case (n = 8)        0.166 (0.116)        0.077        0.254     
                       Control (n = 58)      0.197 (0.140)        0.159        0.235           *p* = 0.474
  ***NAT2\*5/\*5***     Case (n = 11)       −0.496 (0.134)        −0.405       −0.586    
                       Control (n = 80)     −0.479 (0.141)        −0.447       −0.510          *p* = 0.705
  ***NAT2\*5/\*6***     Case (n = 20)       −0.595 (0.122)        −0.536       −0.653    
                       Control (n = 95)     −0.543 (0.132)        −0.516       −0.569          *p* = 0.103
  ***NAT2\*6/\*6***      Case (n = 7)       −0.714 (0.087)        −0.633       −0.795    
                       Control (n = 25)     −0.627 (0.158)        −0.563       −0.691          *p* = 0.173

Discussion {#s4}
==========

Differential effects of acetylation status by different slow acetylation alleles have been suggested previously, but to our knowledge they have not been formally evaluated *in vivo*. Indirect evidence from *in vitro* studies and from clinical association studies suggest that *NAT*2 variant alleles produce different functional effects, implying heterogeneity within the "slow" acetylator phenotype [@pone.0044629-Hein1]. Antituberculosis drug-induced hepatotoxicity risk is particularly high in carriers of the *NAT2\*6/\*6* allele, thus suggesting that these individuals may constitute a subcategory of "very slow" acetylators [@pone.0044629-Huang1], [@pone.0044629-LeiroFernandez1]. These and other clinical association studies (reviewed in [@pone.0044629-Hein1]) suggest that the NAT2 slow acetylator phenotype is heterogeneous, and that multiple slow acetylator phenotypes exist [@pone.0044629-Cascorbi1]. However, no clear association between *NAT2* variant alleles and *in vivo* phenotype categories among slow acetylator individuals has been proved so far. Our findings indicate that the *NAT2\*6* allele cluster is related with the slowest acetylation capacity *in vivo* with a gene-dose effect, thus demonstrating the occurrence of a category of "very slow acetylators" with the genotype *NAT2\*6* in homozygosity. Because of the ethnic origin of the population study, we were unable to dissect the effect of the allele clusters *NAT2\*7* and *NAT2\*14*; it should, however, be emphasized that these clusters are rare in caucasian populations [@pone.0044629-GarciaMartin1] and that the allele frequencies observed in this study are consistent with those reported for other Caucasian individuals [@pone.0044629-GarciaMartin1], [@pone.0044629-Moslehi1].

The effect of *NAT2* variant alleles may vary by substrate or with substrate concentration [@pone.0044629-Hein1]. For instance, it has been shown that the *NAT2\*7* allele cause a different effect in the N-acetyltransferase activity towards 2-aminofluorene and to sulfamethazine [@pone.0044629-Walraven1]. Therefore the findings obtained in this study should not be extrapolated to other *NAT2* substrates without confirmation with every specific substrate. Nevertheless, our findings *in vivo* agree with findings obtained *in vitro* which suggests that the protein level expressed by common *NAT2* alleles is *NAT2\*4*\>*NAT2\*5*\>*NAT2\*6* [@pone.0044629-Hein1], thus suggesting that the differential effect of *NAT2* alleles observed with the probe drug caffeine is likely to be relevant to other NAT2 substrates.

The aims of this study are to refine the phenotype inference of *NAT2* genotyping and the identification of clinically relevant associations of the new genotype categories with cancer risk, differential treatment response or clinical outcome are beyond the aims of the study. Although this study included patients with cancer of the exocrine pancreas and control subjects, no association of *NAT2* genotype categories with pancreatic cancer risk was observed, in agreement with previous studies [@pone.0044629-Agundez4], [@pone.0044629-Bartsch1].

The findings reported in this study show that acetylation capacity *in vivo* is related to different *NAT2* genotypes among slow acetylators, and indicate that variations in the acetylation *NAT2* status among slow acetylator individuals result from the co-dominant expression of the *NAT2\*5* and *NAT2\*6* alleles or haplotypes, whose diplotypes are related to distinct slow acetylation phenotypes. Additional studies are required to go further in the refinement in phenotype inference, particularly in other human populations with different *NAT2* allele frequencies. It may be argued that the difference in function between the variants *NAT2\*5* and *NAT2\*6*, although statistically significant, is a minor difference compared to the function of any genotype containing at least one *NAT2\*4* allele and therefore that the clinical relevance of this difference may be limited. However, *NAT2\*6/\*6* homozygotes show roughly a 30% reduction on enzyme activity as compared to *NAT2\*5/\*5* homozygotes. For comparison, the reduction on enzyme activity between *NAT2\*4* heterozygotes (intermediate acetylators) and *NAT2\*4/\*4* homozygotes (rapid acetylators) in this study is 28%. A 30% reduction in activity among individuals who have a very impaired acetylation capacity may have a higher clinical relevance than a comparable reduction among individuals who have a high acetylation capacity. These findings provide a novel framework for evaluating interactions between *NAT2* genotype and adverse drug reactions or cancer risk.
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